Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

The FDA New Guidelines to Speed the Approval of Gene Therapy. See Also: The Gene Editing Effect

November 17, 2017 0

Important news has come from the FDA, which issued new guidelines to speed the introduction of …

Sangamo: In Vivo Editing of the Gene Behind Hunter Syndrome

November 15, 2017 0

Yes, it is Sangamo’s (SGMO) zinc finger nuclease (ZFN) gene-editing technology, which for the first time …

Halozyme: Helping Immunotherapy Products. Abeona: An Attractive Newcomer to the Stock Market

November 10, 2017 0

Halozyme Therapeutics (HALO) announced that it will present nonclinical data at the 32nd Annual Meeting of the Society …

Cellectis Allogeneic “Off-the-Shelf” CAR T Candidate is Back in Clinical Trial

November 9, 2017 0

A couple of days ago, Cellectis (CLLS), which uses its own proprietary gene editing technology known …

Nektar Therapeutics: Speeding Its Flight Towards the Moon

November 8, 2017 0

Nektar Therapeutics (NKTR) stock rallied, reaching all-time high with positive results in every aspect of the firm’s …

The Week in Review #10

November 6, 2017 0

The Week in Review #10 NO CONSPIRACY THEORIES - But this is what’s happening - In …

Yesterday’s Prohost Stocks’ Performances: NBIX UP $11.85; JUNO UP $11.60 and EXEL UP $1.35

November 3, 2017 0

EXELIXIS For Exelixis’ excellent news, please read our latest article, "Exelixis’ (EXEL) Exceptional Financial Results and …

Exelixis’ Exceptional Financial Results and Corporate Achievements

November 2, 2017 0

Cabozantinib Net Revenue for Q3 is $96.4 million. Total Revenue of $152.5 million Net Income of $81.4 million, Diluted …

Must Read News. See Also: A New Immunotherapy Combination by Incyte and AstraZeneca

October 31, 2017 0

Amgen (AMGN) and Kirin Holdings (Kirin) announced an agreement upon, which Kirin-Amgen, a joint venture between the two …

The Week in Review #9

October 30, 2017 0

The Week in Review #9 KNOCKING DOWN THE BIOTECH STOCKS - Knocking down the biotech companies’ stocks …

Prohost Letter #414

October 25, 2017 0

Prohost Letter #414 GIANTS & DWARFS - We believe it’s a useful idea bringing The Week …

Agenus’ Double News

October 23, 2017 0

Agenus (AGEN) announced that The Food and Drug Administration (FDA) granted marketing authorization to GlaxoSmithKline's (GSK) …

Gilead’s CAR T Drug, Yescarta, is Approved for NHL Resisting Previous Treatments

October 19, 2017 0

As expected by those who welcome good news from publicly-traded firms, the Food and Drug Administration …

Spectrum Pharmaceuticals: Bringing Hope for Patients with EGFR Non-Small-Cell Lung Cancer with Exon 20 Insertion Mutations

October 18, 2017 0

Spectrum Pharmaceuticals (SPPI) announced an oral presentation of interim data from a Phase 2 clinical study …

Exelixis: A Day for Celebrating and Learning

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

The FDA New Guidelines to Speed the Approval of Gene Therapy. See Also: The Gene Editing Effect

Sangamo: In Vivo Editing of the Gene Behind Hunter Syndrome

Halozyme: Helping Immunotherapy Products. Abeona: An Attractive Newcomer to the Stock Market

Cellectis Allogeneic “Off-the-Shelf” CAR T Candidate is Back in Clinical Trial

Nektar Therapeutics: Speeding Its Flight Towards the Moon

The Week in Review #10

Yesterday’s Prohost Stocks’ Performances: NBIX UP $11.85; JUNO UP $11.60 and EXEL UP $1.35

Exelixis’ Exceptional Financial Results and Corporate Achievements

Must Read News. See Also: A New Immunotherapy Combination by Incyte and AstraZeneca

The Week in Review #9

Prohost Letter #414

Agenus’ Double News

Gilead’s CAR T Drug, Yescarta, is Approved for NHL Resisting Previous Treatments

Spectrum Pharmaceuticals: Bringing Hope for Patients with EGFR Non-Small-Cell Lung Cancer with Exon 20 Insertion Mutations

Exelixis: A Day for Celebrating and Learning

Tracing Large Pharmaceutical Companies’ Choices

Spark Therapeutics: Making History

Ardelyx’s Exciting News. Spark Therapeutics: Facing the Moment of Thrilling Truth

KalVista Pharmaceuticals Signs a Lucrative Strategic Agreement with Merck

New Breakthrough Immuno-Oncology Products